Newsletter October 2023
The colorectal cancer (CRC) PDX panel of EPO is part of a high impact study on CRC chemoresistance published in Molecular Cancer
Just recently, a high impact collaborative study has been published in Molecular Cancer ( Kendzia S et al. A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer. Mol Cancer; 2023, 22: 89, PMID: 37248468 )
on computational and functional analyses, which have used the CRC PDX of the oncotrack initiative, to which EPO has contributed a significant panel of CRC PDX models. The study identifies IGF2BP2 as most abundant in CRC, being associated with chemoresistance and which in conclusion represents a potential therapeutic target. The study supports the great value of CRC PDX pre-clinical models to reveal novel mechanisms of chemoresistance and to design new therapeutic resistance overcoming strategies for CRC. (Weblink)